How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine

    Closed for comments This consultation ended on at   Request commenting lead permission

    None References

    Acute treatment of migraine

    1. Kuruvilla DE, Mann JI, Tepper SJ et al. (2022) Phase 3 randomized, double-blind, sham-controlled trial of e-TNS for the acute treatment of Migraine (TEAM). Scientific Reports, 12:5110.

    2. Chou DE, Yugrakh MS, Winegarner D et al. (2019) Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia, 39(1) 3–14.

    3. Chou DE, Gross GJ, Casadei CH et al. (2017) External trigeminal nerve stimulation for the acute treatment of migraine: open-label trial on safety and efficacy, Neuromodulation. 20 (7), 678–683

    4. Kuruvilla D, Mann JI, Schoenen J et al. (2019) Acute treatment of migraine with external trigeminal nerve stimulation: A pilot trial. Cephalalgia Reports, 2: 1–6.

    5. Penning S and Schoenen J (2017) A survey on migraine attack treatment with the Cefaly device in regular users. Acta Neurologica Belgica; 117(2): 547–549.

    6. Beh SC (2020). External trigeminal nerve stimulation: Potential rescue treatment for acute vestibular migraine. Journal of the Neurological Sciences 408 (2020) 116550.

    Prevention of migraine

    1. Schoenen J, Vandersmissen B et al. (2013). Migraine prevention with a supraorbital transcutaneous stimulator. A randomized controlled trial. Neurology, 80:697–704.

    Schoenen JE (2016). Migraine prevention with a supraorbital transcutaneous stimulator: a randomised controlled trial. Neurology 86, 201–2.

    1. Deng Y, Zheng M, He L et al. (2020) A head-to-head comparison of percutaneous mastoid electrical stimulator and supraorbital transcutaneous stimulator in the prevention of migraine: a prospective, randomized controlled study. Neuromodulation, 23 (6), 770-777.

    2. Jiang L, Yuan DL, Li M et al. (2019) Combination of flunarizine and transcutaneous supraorbital neurostimulation improves migraine prophylaxis. Acta Neurol. Scand. 139 (3), 276–283.

    3. Przeklasa-Muszynska A, Skrzypiec K, Kocot-Kepska M et al. (2017) Non-invasive transcutaneous Supraorbital Neurostimulation (tSNS) using Cefaly((R)) device in prevention of primary headaches, Neurol. Neurochir. Pol. 51 (2), 127–134 (Epub 2017/02/06)

    4. Magis D, Sava S et al. (2013) Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2313 headache sufferers in the general population. The Journal of Headache and Pain. 10.1186/1129-2377-14-95

    5. Danno D, Ligaya M, Imai N et al. (2019) The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients. Nature: scientific reports 9:9900, 1-7.

    6. Birlea M, Penning S, Callahan K et al. (2019) Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: An open-label trial. Cephalalgia Reports, 2: 1–10.

    7. FDA (MAUDE database) Date searched 25-03-2015. MAUDE Adverse Event Report: CEFALY TECHNOLOGY CEFALY https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/Detail.CFM?MDRFOI__ID=4181806